Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems
| Autor: | Yinnong Zhao, Le-Qun Li, Liang Ma, Hai-Ming Ru, Jian-Hong Zhong |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Gastrointestinal Stromal Tumors medicine.drug_class medicine.medical_treatment Antineoplastic Agents Gastroenterology Piperazines Tyrosine-kinase inhibitor hemic and lymphatic diseases Internal medicine medicine Humans neoplasms Gastrointestinal tract Chemotherapy business.industry Standard treatment Cancer Imatinib medicine.disease digestive system diseases Radiation therapy Pyrimidines Imatinib mesylate Chemotherapy Adjuvant Benzamides Imatinib Mesylate business medicine.drug |
| Zdroj: | Scandinavian Journal of Gastroenterology. 46:645-651 |
| ISSN: | 1502-7708 0036-5521 |
| DOI: | 10.3109/00365521.2011.551884 |
| Popis: | To review the current situation and find out the current problems of adjuvant imatinib for gastrointestinal stromal tumors (GISTs).Searching for articles and records about imatinib for GISTs, especially adjuvant imatinib for GISTs, on MEDLINE, EMBASE and international conference on gastrointestinal.GISTs are derived from mesenchymal cells of the gastrointestinal tract. The standard treatment for primary GISTs is to resect the tumor together with the negative margins completely without tumor rupture and spillage. Conventional chemotherapy and radiotherapy is ineffective for advanced GISTs. The introduction of imatinib has dramatically changed the natural history of advanced GISTs. Imatinib is generally safe and effective with doses of 400, 600 or 800 mg daily, and has become the standard drug in the treatment for patients with advanced GISTs. Furthermore, most of the toxicity of imatinib is minimal and manageable, almost no treatment-related deaths have been reported. Therefore, adjuvant imatinib therapy is safe and seems to improve recurrence-free survival after the resection of primary GISTs.Although U.S Food and Drug Administration and European Medicines Agency have approved the use of adjuvant imatinib for GISTs postoperatively, a series of questions about the use of adjuvant imatinib still exist, such as the impact of adjuvant imatinib on overall survival, the optimal dose, the best duration of treatment and the most suitable patients. Doctors and patients should weigh the pros (the decrease of relapse) and cons (drug toxicity and drug costs), especially in terms of the benefit of overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|